Dr. Ginil Kumar P. currently serves as Professor at the Department of Urology, School of Medicine, Kochi.


Publication Type: Journal Article

Year of Publication Title


A. Laddha, Bijalwan, P., Appu Thomas, and Kumar, Gb, “Small Renal Mass with Level 4 IVC Thrombus”, Indian J Surg Oncol, vol. 10, no. 1, pp. 196-198, 2019.


G. Mohan Sali, Nair, K. R., Bindhu, M. R., Kumar, Gb, Sanjeevan, K. V., and Appu Thomas, “Primary Malignant Melanoma of Urethra-Our Experience with 2 Cases”, Indian J Surg Oncol, vol. 10, no. 1, pp. 137-140, 2019.


J. Mariam Joshua, Meenu Vijayan, and Kumar, Gb, “A retrospective analysis of patients treated with intravesical BCG for high-risk nonmuscle invasive bladder cancer.”, Ther Adv Urol, vol. 11, p. 1756287219833056, 2019.[Abstract]

<p><b>Background: </b>Adjuvant intravesical immunotherapy with Bacillus Calmette-Guerin (BCG) is considered as the first-line agent in patients with high-risk nonmuscle invasive bladder cancer (NMIBC) after surgery. There are no data in India where there is a high prevalence of tubercle bacillus and inherent immunity against sp. The present study aims to evaluate the outcomes of intravesical BCG in the Indian population.</p>

<p><b>Methods: </b>A retrospective study of 101 patients who underwent intravesical BCG for high-risk NMIBC between January 2006 and December 2015 was carried out in a single centre. We compared the recurrence-free rate and progression rate of patients who received induction alone and induction with maintenance BCG therapy. The safety profile of intravesical BCG therapy was also assessed in the study.</p>

<p><b>Results: </b>After a median follow up of 2 years, the disease-free survival (DFS) rates of the induction group and maintenance group were 82% and 88% respectively ( = 0.233). There was no difference in progression-free survival (PFS) rates at 2 years in those who receive maintenance BCG (95%) and those with induction BCG (94.7%; = 0.721). A total of 69.36% of our patients had local adverse events.</p>

<p><b>Conclusion: </b>Our results suggest that maintenance therapy does not enhance the therapeutic effects of BCG in patients who respond favourably to 6 weeks of induction. Additional prospective studies are warranted in those countries where tuberculosis exposure is prevalent.</p>

More »»


Aa Purushothaman, Kumar, Gb, Gangadharan, Pc, and Roshni P. R., “A comparison of leuprolide acetate versus bilateral orchiectomy for patients with metastatic prostate cancer”, Asian Journal of Pharmaceutical and Clinical Research, vol. 9, pp. 51-54, 2016.[Abstract]

Objective: Prostate cancer is the most common visceral malignancy and leading cause of cancer-related death in men. Androgen deprivation therapy is the established treatment of metastatic prostate cancer and has different approaches in the reduction of androgen activity including surgical castration (bilateral orchiectomy) and medical castration (luteinizing hormone-releasing hormone agonists/antagonists). Our purpose was to study the clinical profile, effectiveness, and outcome of South Indian patients with metastatic prostate cancer undergoing treatment with surgical and medical castration. Methods: A total of 30 surgical and 30 medical castration patients diagnosed with metastatic prostate cancer between (2008 and 2009) were followed up to 5 years. Serum prostate specific antigen (PSA) levels at the time of the first diagnosis, post-treatment nadir PSA levels, time to nadir PSA, time to hormonal resistance between the study groups were assessed, retrospectively. The Kaplan–Meier method was used with log-rank test for survival rate calculations. Gleason score, PSA levels, skeletal-related events, and sites of metastasis of the study groups were studied. Result: The average survival time after medical castration was 60 months and 42 months for surgical castration. No significant difference could be established between the groups. Bone was the most common site of metastasis and radiation was the major skeletal-related events in medical groups. Conclusion: There were no statistical differences between the groups in terms of treatment modalities in metastatic prostate cancer. © 2016, Innovare Academics Sciences Pvt. Ltd. All rights reserved.

More »»